How does Benlysta work for lupus?
Benlysta works by attaching to a specific protein, called B-lymphocyte stimulator (BLyS), preventing it from binding to its receptors on B cells. BLyS is important for the growth and development of B cells, and B cells have a crucial role in the development of lupus. Certain B cells, called autoreactive B-cells, stay in the body for longer than they should in people with lupus, producing autoantibodies that target important cellular components, such as DNA, causing disease flares. By binding to BLyS, Benlysta prevents the survival of B-cells and their differentiation into immunoglobulin-producing plasma cells.
Benlysta is a biologic therapy, not a steroid. It may be called a B-cell depleting therapy or a selective immunosuppressant.
References
Benlysta (belimumab). Updated 04/2024. FDA Package Insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761043s027lbl.pdf
Read next
What is the difference between Benlysta and Saphnelo?
Benlysta and Saphnelo are both targeted treatments, but they target different parts of the immune system that are particularly overactive in lupus. Benlysta targets and blocks the activity of a type of white blood cell called a B cell, which produces antibodies that attack tissue, causing symptoms of SLE. It is classified as a B-lymphocyte stimulator (BLyS)-specific inhibitor. Saphnelo targets the type I interferon receptor and inhibits the activity of type 1 interferons. Activation of the interferon system is a common underlying characteristic of SLE that leads to the immune system being constantly “switched on”, contributing to SLE symptoms. Saphnelo is classified as a type 1 interferon receptor antagonist. Benlysta was first approved in 2011 and Saphnelo was approved in 2021. Continue reading
What's the difference between Lupkynis and Benlysta?
Benlysta injection is approved to treat adults and children 5 years of age and older with systemic lupus erythematosus (SLE) and active lupus nephritis (lupus-related kidney inflammation), while oral Lupkynis is only approved to treat lupus nephritis in adults. Lupkynis has not yet been approved for use in children Continue reading
Does Benlysta cause weight gain?
Although weight gain is not listed as a side effect of Benlysta in the product information, a phase IV clinical study that analyzed side effect information from 14,100 people who had taken Benlysta reported weight gain as a side effect for 2.87% of them (404 people). Continue reading
Related medical questions
- Where do you inject Benlysta?
- How long does it take for Benlysta injections to work?
- Can Benlysta cause an allergic reaction?
- How does Benlysta help lupus?
- How long does a Benlysta infusion take?
- Does Benlysta cause hair loss?
- Does Benlysta help with fatigue?
- How does the Benlysta copay program work?
- Common FAQs for Lupus Treatment
- How to inject Benlysta with the autoinjector?
Drug information
Related support groups
- Benlysta (14 questions, 34 members)
- Belimumab (2 questions, 8 members)
- Systemic Lupus Erythematosus (49 questions, 342 members)